Sugi Predict

Sugi Predict / Compounds / SCHEMBL21798404

SCHEMBL21798404

SCHEMBL21798404

CCOC(=O)C1(S(=O)(=O)C(C)(C)COC)CC1

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 2/20 0.34
▸ CYP2D6 P10635 2/20 0.34
▸ CYP2C9 P11712 2/20 0.34
▸ CYP2C19 P33261 2/20 0.34
▸ ALDH1A1 P00352 4/20 0.34
▸ KMT2A Q03164 3/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ HTT P42858 2/20 0.34
▸ NPSR1 Q6W5P4 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ MAPK1 P28482 1/20 0.33
▸ MEN1 O00255 2/20 0.32
▸ LMNA P02545 2/20 0.32
▸ GAA P10253 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ POLB P06746 2/20 0.30
▸ OPRM1 P35372 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3515327 0.77 CYP3A4 (0.37) CYP3A4CYP2D6CYP2C9CYP2C19ALDH1A1
SCHEMBL25588835 0.72 CA12 (0.32) NPSR1
SCHEMBL21798307 0.72 NPSR1 (0.42) CYP3A4CYP2D6CYP2C9CYP2C19ALDH1A1
SCHEMBL21798037 0.72 CYP3A4 (0.40) CYP3A4CYP2D6CYP2C9CYP2C19ALDH1A1
SCHEMBL13049339 0.72 CYP3A4 (0.40) CYP3A4CYP2D6CYP2C9CYP2C19ALDH1A1
SCHEMBL30772891 0.71 CYP3A4 (0.47) CYP3A4CYP2D6CYP2C9CYP2C19ALDH1A1
SCHEMBL23675642 0.68 HCRTR2 (0.36) ALDH1A1KMT2AMEN1GAA
SCHEMBL21798007 0.68 LMNA (0.33) LMNA
SCHEMBL21798342 0.67 KMT2A (0.39) ALDH1A1KMT2ASMN1; SMN2NPSR1CYP1A2
SCHEMBL21798122 0.66 NPSR1 (0.41) CYP3A4CYP2D6CYP2C9CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466821-B2 Antiviral pyridopyrazinedione compounds NOVARTIS AG (CH) 2025-11-11 — — US disclosed
US-20230052629-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2023-02-16 — — US disclosed
US-20230052629-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2023-02-16 — — US disclosed
US-11072610-B2 Antiviral pyridopyrazinedione compounds NOVARTIS AG (CH) 2021-07-27 — — US disclosed
US-11072610-B2 Antiviral pyridopyrazinedione compounds NOVARTIS AG (CH) 2021-07-27 — — US disclosed
EP-3849979-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS Novartis AG (CH) 2021-07-21 — — EP disclosed
CN-112996789-A Antiviral pyridopyrazinedione compounds 诺华股份有限公司 2021-06-18 — — CN disclosed
WO-2020053654-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS NOVARTIS AG (CH) 2020-03-19 — — WO disclosed
US-20200079772-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS NOVARTIS AG (CH) 2020-03-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466821-B2 Antiviral pyridopyrazinedione compounds ZC3HAV1, IL5, TYMP CYP3A4 79/4885CYP2D6 103/4885CYP2C9 491/4885
US-20230052629-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS ZC3HAV1, IL5, TYMP CYP3A4 79/4885CYP2D6 103/4885CYP2C9 491/4885
US-11072610-B2 Antiviral pyridopyrazinedione compounds ZC3HAV1, IL5, TYMP CYP3A4 79/4885CYP2D6 103/4885CYP2C9 491/4885
US-20200079772-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS ZC3HAV1, IL5, TYMP CYP3A4 79/4885CYP2D6 103/4885CYP2C9 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.